During 24th IUCr 2017 Congress, a semi-formal program will run in parallel to the scientific sessions.

It will include:

  • discussions and roundtables on education, outreach and capacity building;
  • seminars on general interest topics;
  • contests for research grants for youngsters;
  • real and operational single-crystal XRD lab to collect your own data;
  • exhibitions;
  • Dragons’ Den contest (registered paid-up students only) – win INR 1,50,000 to support your dream research project. Click here
  • and much more …

For further information on the parallel program please contact M Zema on zema@iucr2017.org


Mega structure build

Supported by:

GOI-logoÖKF_delhi_logo

The world’s largest crystal structure model, which has been entered in the Guinness Book of Records, is being brought in from Vienna. This model will be exhibited at the venue. The creator, Dr Robert Krickl, is a fantastic communicator and will help explain the model. This project has been initiated because of a handsome seed contribution from Department of Science and Technology, Govt. of India and grants from The Austrian Culture Forum, Govt of Austria. This amount is a partial donation towards this mega project.

parallel-pgrm-img


Salt of the Earth

150 minute session on various aspects of this unique compound, Sodium Chloride, that is so important in crystallography and also elsewhere. Chair: G.R. Desiraju. Speakers: Robert Krickl (Vienna), Dr. Harshvardhan (Hon’ble Minister, S&T, Govt. of India), Mike Glazer (Oxford), Artem Oganov (SUNY), Amitava Das (CSMCRI).


Academia/Industry/Government Collaborations in Drug Design and Drug Development
(22 August 1455 to 1730 hours)

150 minutes session on academia/industry/government interaction in the area of solid state pharma and novel crystal forms for innovator and generic companies. Speakers represent academic, industrial and government agencies both in India and abroad.

Chair: G. Sahni, Director-General, CSIR India.

Speakers:

  • G.R. Desiraju (IISc, Bangalore) will present a survey of solid forms that are of significance in the development of new drugs and why they are expected to show promise in the near future. Salts, cocrystals, solvates and amorphous forms are different solid state variations of a drug. Any of these forms is capable of existing in polymorphic modifications. All this greatly increases the structural landscape which the drug inhabits: this is turn is expected to be the key to property modulation. Notable among the properties that can be modified are solubility and permeability, thereby affecting bioavailability. The core inputs for this and related activity arises from the field of crystal engineering and the possibilities for logic driven solid state synthesis through supramolecular heterosynthons. His talk title, “API solid forms and the crystal structure landscape”.

  • S.R. Byrn (Purdue, USA), will summarize the regulatory science of solid-state chemistry. The FDA defines regulatory science as the science of developing new tools, standards, and approaches to address safety, efficacy, and quality. The role of solid-state chemistry will be outlined. The Q1/Q2/Q3 approach to determine equivalence will be used: Q1 – same ingredients, Q2 – same amounts of ingredients, and Q3 has a broader meaning related to same structure, microstructure, and physical/chemical properties. From the perspective of solid-state chemistry, Q3 would mean same solid-state structure. The determination of Q3 involves a range of crystallographic studies including powder diffraction, single crystal studies, and pair distribution function analysis. The title of his talk is: Regulatory Science and the Solid State Chemistry of Drugs.

  • G. Sahni (CSIR Headquarters) will describe his experiences with drug design based on macromolecular crystallography. Critical and intricate structural details associated with streptokinase, a bacterial thrombolytic protein, were gleaned from X-ray and solution studies to design newer drug candidates with smarter and clinically useful functions. Crystallography is important in drug design and redesign, as well as in gaining deep mechanistic insights but when the resolution is limited, the available structures do not represent the full complement of polypeptide partners relevant to the biology of the multi-component system. Streptokinase represents one such example. His talk title: Quasi-structural studies in the redesign of a clot-buster protein drug.

  • R. K. Khandal (India Glycols)
  • A. Venkateswarlu (DRILS, Hyderabad), will present a high level SWOT analysis of pharmaceutical cocrystals and their potential role in design and development of therapeutics. The emerging impact of cocrystals as alternate solid forms with pharmaceutical applications, both in the drug substance and the drug product, presents itself as a powerful opportunity to address unmet medical needs. Typically, the landscape of new chemical entities (NCEs) and active pharmaceutical ingredients (APIs) has been dominated by solid forms, involving either the native chemical forms or salts, solvates and corresponding polymorphs thereof. Cocrystal forms of such NCEs or APIs as novel compositions of matter offer not only IP potential but also non-obvious therapeutic profile coupled with means to favorably impact the life cycle management. His talk title, “Pharmaceutical Cocrystals: a SWOT Perspective”.


Dragon’s Den:

Supported by:

iucr-170208  stoe-170208  Elsevier-170208  

Young researchers (at the level of post-doc; maximum age 35 years, researchers with a permanent academic position excluded; no restriction on country of origin or affiliation; should be registered for participation in IUCr 2017 Congress) submit the idea for a research project (max. 200 words) to a committee of panelists. 20 candidates are selected to present their project in public and in front of the panel. Decision on what projects are funded is taken immediately at the end of all presentations. Awardees receive a grant of INR 1,50,000 or the equivalent per project.